SearchProfile
Chandra P. Belani, M.D.Miriam Beckner Distinguished Professor of Medicine Penn State Milton S. Hershey Medical Center Deputy Director Penn State Hershey Cancer InstituteOffice Location
Penn State Hershey Cancer Institute
500 University Drive Hershey, PA 17033
Tel: 800-243-1455 / 717-531-6585
Fax: 717-531-0429
Specialties
Medical Oncology
Patient Services Provided
Lung & Thoracic Malignancies
Practice LocationsBiographical InformationDr. Chandra Belani is Deputy Director of the Penn State Hershey Cancer Institute (PSHCI), and Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey Medical Center & College of Medicine.
Professional Education
Fellowship,
Hematology,
University of Maryland Medical System (Baltimore)
(1988)
Residency,
Internal Medicine,
North General Hospital (New York)
(1985)
Residency,
Internal Medicine,
University of Maryland Medical System (Baltimore)
(1984)
M.D.,
Sawai Man Sigh Medical College
(1981)
Research Interests
Dr. Belani directs translational and clinical investigations across all programs and the disease teams at the PSHCI. Dr. Belani is internationally renowned for his accomplishments in the area of lung cancer therapeutics and new drug development. His research efforts have led to changes in the treatment paradigms for lung cancer. Dr. Belani plays a key role in moving promising new discoveries for the treatment of all solid malignancies from the laboratory to the clinic and serves as a leader for early phase clinical trials at the PSHCI.
Publications
Gutheil JC, Hart SR, Belani CP, Melera PW, Hussain A
Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin Journal of Biological Chemistry 18; 269(11):7976-81, 1994 Schiller J, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Junming Z, Johnson D Comparison of four chemotherapy regimens in advanced non-small cell lung cancer New England Journal of Medicine, 346(2)92-98, 2002 Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ Randomized, Phase III Study of Weekly Paclitaxel in Combination with Carboplatin versus Standard every-3-weeks administration of Carboplatin and Paclitaxel for Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer Journal of Clinical Oncology 26(3), 468-73, 2008 Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu L, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP Maintenance Pemetrexed Plus Best Supportive Care (BSC) Versus Placebo Plus BSC: A Phase III Study in Advanced NSCLC Lancet 374(9699):1432-40, 2009 Ramalingam SS, Maitland ML, Frankel P, Argiris A, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara D, Belani CP Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer Journal of Clinical Oncology, 1:28(1):56-62, 2010 |
Share This
Printer Friendly